Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 10.07B |
| Revenue (ttm) | 944.05M |
| Net Income (ttm) | -268.22M |
| Shares Out | 159.39M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,471,495 |
| Open | 63.85 |
| Previous Close | 64.04 |
| Day's Range | 63.07 - 64.61 |
| 52-Week Range | 23.95 - 64.72 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 67.88 (+7.47%) |
| Earnings Date | Nov 5, 2025 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE... [Read more]
Financial Performance
In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for IONS stock is "Buy." The 12-month stock price target is $67.88, which is an increase of 7.47% from the latest price.
News
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally...
Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)
After years of futility, Ionis' recent regulatory and clinical successes have spurred optimistic market attention. I review Q2/2025 earnings documents together with 09/04/2025 CEO Monia interview and ...
Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference ...
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status
On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.'s IONS ION582 for Angelman syndrome (AS), a rare neurological disorder.
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 fo...
Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 3:00 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference ...
Ionis to host investors and analysts for Innovation Day 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York. The agenda will feature p...
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call ...
Is The 35% Rally In IONS Stock Just The Beginning?
Ionis Pharmaceuticals' stock jumped 35% on September 2, 2025, after positive late-stage clinical trial results for olezarsen, a therapy for severe hypertriglyceridemia (sHTG). Investor enthusiasm is a...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo...
Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Positive CORE and CORE2 Topline Results Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sot...
Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news
Ionis Pharmaceuticals stock jumped 31% on Tuesday hitting a new 52-week high after breakthrough news that lit up investor interest and boosted confidence across the biotech sector.
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction
Ionis Pharmaceuticals, Inc. IONS on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).
Ionis shares jump after drug lowers blood fat levels in advanced trials
Ionis Pharmaceuticals' shares surged on Tuesday before the bell after the drugmaker said its experimental treatment significantly reduced levels of blood fats called triglycerides and reduced pancreat...
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with sever...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma
Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary...
US FDA approves Ionis' drug for rare genetic disorder
The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder.
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to ...
Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug
Ionis Pharmaceuticals Inc. IONS reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.
Ionis reports second quarter 2025 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025. “Dur...
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases
Stanley Crooke, Ionis Pharmaceuticals founder and n-Lorem founder, joins 'Squawk Box' to discuss the fight against rare diseases, the development of ASO technology, and more.
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with...